Dopaminergic regulation of fetal growth hormone (GH) secretion: study with maternal administration of bromocriptine

Giuseppe Robuschi, Mara Montermini, Paolo Chiodera, Eliana Gardini, Mario Salvi, Elisabetta Borciani, Angelo Gnudi, Elio Roti

Research output: Contribution to journalArticle

Abstract

To investigate the role of dopaminergic pathways on the control of growth hormone (GH) secretion, bromocrip-tine (BMC), a dopamine agonist drug, was orally administered at the dose of 5 mg to 46 pregnant women during labor whereas 41 received placebo. Maternal blood was obtained before drug administration and at delivery. Cord blood was obtained at delivery. Following the interval of time elapsed between BMC or placebo ingestion and parturition, maternal and cord blood sam- ples were divided in 7 groups for statistical analysis. Cord blood GH resulted significantly higher than the corresponding maternal value (p <0.001). No significant change in GH values was observed nor in samples of mothers treated with BMC compared to mothers treated with placebo neither in cord blood samples of the corresponding neonates. These findings indicate that BMC administration does not modify GH secretion in the term fetus.

Original languageEnglish
Pages (from-to)345-349
Number of pages5
JournalJournal of Perinatal Medicine
Volume15
Issue number4
DOIs
Publication statusPublished - 1987

Keywords

  • Bromocriptine
  • fetal growth hormone

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'Dopaminergic regulation of fetal growth hormone (GH) secretion: study with maternal administration of bromocriptine'. Together they form a unique fingerprint.

  • Cite this